The study of usefulness and safety of pregabalin for numbness of spinal disease

The study of usefulness and safety of pregabalin for numbness of spinal disease - The effect of pregabalin for the numbness of the spine disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026889

Enrollment

Registered

2017-04-09

Start date

2017-04-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spine and Spinal cord disease

Interventions

Test drug name: product name (common name) Lyrica (pregabalin) Manufacturer selling agency / Sales alliance: Pfizer Inc. / Eisai Co., Ltd. As an initial dose, pregabalin 150 mg / day is administered

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients complaining numbness of due to spine and spinal cord diseases. 2.Patients undergoing conservative therapy 3.Subjects who gained document consent by free will with sufficient understanding after the principal received sufficient explanation for participation in this study.

Exclusion criteria

Exclusion criteria: 1.Patients with a history of hypersensitivity to pregabalin. 2.Patients who were the subject of surgical treatment. 3.Patients who are judged inappropriate as the subject by reserch director.

Design outcomes

Primary

Measure	Time frame
The degree of numbness(VAS)	—

Secondary

Measure	Time frame
The degree of pain(VAS) The score of sleep disturbance	—

Countries

Japan

Contacts

Public ContactTakeshi Hara

Juntendo university Department of Neurosurgery

thara79nouge@gmail.com03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026